Skip to main content

Table 3 Summary of adverse events and discontinuations over time in the total population

From: Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

  Month Post-month 48 (n = 99)
0–6 6–12 12–18 18–24 24–30 30–36 36–42 42–48
(n = 486) (n = 455) (n = 430) (n = 405) (n = 343) (n = 309) (n = 293) (n = 207)
Adverse events 379 (78.0) 310 (68.1) 254 (59.1) 215 (53.1) 178 (51.9) 170 (55.0) 145 (49.5) 80 (38.6) 58 (58.6)
Discontinuations due to adverse events 26 (5.3) 19 (4.2) 21 (4.9) 7 (1.7) 13 (3.8) 8 (2.6) 12 (4.1) 1 (0.5) 7 (7.1)
Discontinuations due to serious adverse events 15 (3.1) 16 (3.5) 10 (2.3) 7 (1.7) 6 (1.7) 6 (1.9) 8 (2.7) 1 (0.5) 6 (6.1)
Discontinuations due to serious infection events 6 (1.2) 7 (1.5) 4 (0.9) 4 (1.0) 3 (0.9) 3 (1.0) 5 (1.7) 0 (0.0) 3 (3.0)
  1. Data are number (%)